16 employees
Psyence develops natural psilocybin products for the treatment of psychological trauma and mental health disorders
2019
$1.4M
from 1 investors over 1 rounds
Psyence Group raised $1.4M on March 23, 2023
Investors: Cantheon Capital, LLC